<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203311429815</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203311429815</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Prognostic factors for survival in systemic lupus erythematosus associated pulmonary hypertension</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Chow</surname><given-names>SL</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311429815">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Chandran</surname><given-names>V</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311429815">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Fazelzad</surname><given-names>R</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311429815">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Johnson</surname><given-names>SR</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311429815">1</xref>
<xref ref-type="aff" rid="aff1-0961203311429815">3</xref>
<xref ref-type="corresp" rid="corresp1-0961203311429815"/>
</contrib>
</contrib-group>
<aff id="aff1-0961203311429815"><sup>1</sup>Division of Rheumatology, Department of Medicine, University Health Network, University of Toronto, Toronto, Canada; <sup>2</sup>University Health Network Health Sciences Library, Toronto, Canada; and <sup>3</sup>University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Canada</aff>
<author-notes>
<corresp id="corresp1-0961203311429815">Sindhu Johnson, Division of Rheumatology, Ground Floor, East Wing, Toronto Western Hospital, 399 Bathurst Street, Toronto, Ontario, Canada, M5T 2S8 Email: <email>Sindhu.Johnson@uhn.on.ca</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>21</volume>
<issue>4</issue>
<fpage>353</fpage>
<lpage>364</lpage>
<history>
<date date-type="received"><day>7</day><month>1</month><year>2011</year></date>
<date date-type="accepted"><day>20</day><month>10</month><year>2011</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2011. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p><bold>Objective:</bold> Pulmonary hypertension (PH) is a rare but severe manifestation of systemic lupus erythematosus (SLE) that can ultimately result in death. The identification of factors that prognosticate survival in SLE-PH is necessary for appropriate monitoring, timing of therapeutics and lung transplantation. The primary objective of this study was to identify prognostic factors for survival in SLE-PH through review of the literature. The methodological quality of the prognostic studies was also evaluated<italic>.</italic> <bold>Methods:</bold> A systematic review of the literature was performed to identify studies evaluating prognostic factors for survival in SLE-PH. Medline, EMBASE, CINAHL, and Cochrane Central Registry of Controlled Trials (inception – week 2 2010) were searched. A standardized abstraction form was used by two independent reviewers to extract prognostic factors. Methodological quality was evaluated using a validated quality index. <bold>Results:</bold> Twenty-three observational studies from 375 citations were evaluated. Elevated mean pulmonary artery pressure, Raynaud’s phenomenon, thrombocytopenia, plexiform lesion, infection, thrombosis, pregnancy, pulmonary vasculitis and anticardiolipin antibodies were associated with decreased survival. Lupus disease activity, nephritis and central nervous system disease were not associated with survival. The sample sizes were small and methodological quality of the studies was variable. <bold>Conclusion:</bold> This study summarizes factors that may be associated with decreased survival in SLE-PH. The small sample sizes and variable methodological quality preclude definitive conclusions. This study provides the groundwork for further research using large cohorts.</p>
</abstract>
<kwd-group>
<kwd>Prognosis</kwd>
<kwd>pulmonary arterial hypertension</kwd>
<kwd>review</kwd>
<kwd>survival</kwd>
<kwd>systemic lupus erythematosus</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203311429815" sec-type="intro"><title>Introduction</title>
<p>Systemic lupus erythematosus (SLE) is a multisystem disease that can affect the lungs. Pulmonary hypertension (PH) is one manifestation that has devastating consequences, with shortness of breath, impairment of quality of life and mortality.<sup><xref ref-type="bibr" rid="bibr1-0961203311429815">1</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr3-0961203311429815">3</xref></sup> The prevalence of SLE associated PH is estimated to be 1–14%.<sup><xref ref-type="bibr" rid="bibr3-0961203311429815">3</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr6-0961203311429815">6</xref></sup> Variations in the estimated prevalence may be attributable to differences in the SLE population studied and the criteria used for diagnosis.<sup><xref ref-type="bibr" rid="bibr7-0961203311429815">7</xref></sup> Historically, studies have used a variety of thresholds for right ventricular systolic pressure (ranging from 30 to 45 mmHg) on echocardiogram,<sup><xref ref-type="bibr" rid="bibr3-0961203311429815">3</xref>,<xref ref-type="bibr" rid="bibr8-0961203311429815">8</xref></sup> while more recent studies have relied on cardiac catheterization measurements to make the diagnosis. Others have argued that studies may underestimate the true prevalence, since clinically severe or symptomatic patients are referred to academic centers.<sup><xref ref-type="bibr" rid="bibr9-0961203311429815">9</xref></sup></p>
<p>SLE-PH patients have been shown to be similar to SLE patients without PH with respect to age and gender. In Canadian, Chinese, and Japanese cohorts, SLE-PH patients had age of onset ranging between 30 and 39 years old, and a mean SLE disease duration ranging between 3 and 9 years after SLE diagnosis.<sup><xref ref-type="bibr" rid="bibr5-0961203311429815">5</xref>,<xref ref-type="bibr" rid="bibr8-0961203311429815">8</xref>,<xref ref-type="bibr" rid="bibr10-0961203311429815">10</xref>,<xref ref-type="bibr" rid="bibr11-0961203311429815">11</xref></sup> SLE-PH has been associated with the presence of antibodies to ribonucleoprotein (anti-RNP),<sup><xref ref-type="bibr" rid="bibr10-0961203311429815">10</xref>,<xref ref-type="bibr" rid="bibr12-0961203311429815">12</xref>,<xref ref-type="bibr" rid="bibr13-0961203311429815">13</xref></sup> rheumatoid factor,<sup><xref ref-type="bibr" rid="bibr4-0961203311429815">4</xref>,<xref ref-type="bibr" rid="bibr12-0961203311429815">12</xref></sup> Raynaud’s phenomenon,<sup><xref ref-type="bibr" rid="bibr2-0961203311429815">2</xref>,<xref ref-type="bibr" rid="bibr5-0961203311429815">5</xref>,<xref ref-type="bibr" rid="bibr14-0961203311429815">14</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr21-0961203311429815">21</xref></sup> digital vasculitis,<sup><xref ref-type="bibr" rid="bibr2-0961203311429815">2</xref>,<xref ref-type="bibr" rid="bibr21-0961203311429815">21</xref></sup> livedo reticularis,<sup><xref ref-type="bibr" rid="bibr2-0961203311429815">2</xref>,<xref ref-type="bibr" rid="bibr21-0961203311429815">21</xref></sup> and elevated levels of endothelin-1.<sup><xref ref-type="bibr" rid="bibr20-0961203311429815">20</xref></sup> The association of SLE-PH with antiphospholipid antibodies<sup><xref ref-type="bibr" rid="bibr6-0961203311429815">6</xref>,<xref ref-type="bibr" rid="bibr8-0961203311429815">8</xref>,<xref ref-type="bibr" rid="bibr12-0961203311429815">12</xref>,<xref ref-type="bibr" rid="bibr22-0961203311429815">22</xref>,<xref ref-type="bibr" rid="bibr23-0961203311429815">23</xref></sup> and disease activity<sup><xref ref-type="bibr" rid="bibr1-0961203311429815">1</xref>,<xref ref-type="bibr" rid="bibr8-0961203311429815">8</xref>,<xref ref-type="bibr" rid="bibr22-0961203311429815">22</xref>,<xref ref-type="bibr" rid="bibr24-0961203311429815">24</xref>,<xref ref-type="bibr" rid="bibr25-0961203311429815">25</xref></sup> is controversial. Fois et al. reported that systolic pulmonary artery pressure (PAP) ≥35 mmHg was more common in subjects of African descent (50% vs. 20%, <italic>p</italic> = 0.03), in patients with longer disease duration (14 ± 8 versus 9.5 ± 8 years, <italic>p</italic> = 0.049), history of peripheral nervous system involvement (25% versus 4%, <italic>p</italic> = 0.02), pericarditis (58% versus 27%, <italic>p</italic> = 0.04), anti-Sm (42% versus 11%, <italic>p</italic> = 0.01), and anticardiolipin antibodies (75% versus 31%, <italic>p</italic> = 0.007).<sup><xref ref-type="bibr" rid="bibr26-0961203311429815">26</xref></sup></p>
<p>Survival in SLE-PH is poor. SLE-PH patients have a higher mortality rate than those without PH. One retrospective cohort study reported a 3-year survival rate of 44.9% and a 5-year survival rate of 16.8%.<sup><xref ref-type="bibr" rid="bibr3-0961203311429815">3</xref></sup> Asherson et al. found a 2-year mortality greater than 50%.<sup><xref ref-type="bibr" rid="bibr1-0961203311429815">1</xref>,<xref ref-type="bibr" rid="bibr2-0961203311429815">2</xref></sup> PH is the third most common cause of death in Korean SLE patients.<sup><xref ref-type="bibr" rid="bibr27-0961203311429815">27</xref></sup> SLE-PH patients have a shorter time from diagnosis to death than idiopathic pulmonary arterial hypertension (IPAH) patients.<sup><xref ref-type="bibr" rid="bibr3-0961203311429815">3</xref></sup> Interestingly, more SLE-PH patients than IPAH patients die from infection, suggesting that these patients may be more susceptible to infection due to disease itself or concurrent immunosuppressive therapy.<sup><xref ref-type="bibr" rid="bibr3-0961203311429815">3</xref></sup> It has been suggested that SLE-PH patients have a better prognosis than systemic sclerosis associated-PH (SSc-PH) patients, in whom Condliffe et al. reported a 3-year survival rate of 75% in SLE-PH compared with 47% in SSc-PH patients in the United Kingdom (<italic>p</italic> = 0.01).<sup><xref ref-type="bibr" rid="bibr28-0961203311429815">28</xref></sup></p>
<p>The identification of factors that prognosticate survival for those with SLE-PH is needed for optimal care of these patients: appropriate monitoring, timing of therapeutic interventions and lung transplantation. Screening recommendations are difficult unless population subsets at higher risk can be identified. Knowledge of factors that prognosticate worse outcome for patients with SLE-PH may have significant clinical utility. Before additional research is undertaken, a review of the current state of knowledge is warranted to determine prognostic factors that have clinical utility. Therefore, the objective of our study was to systematically review the medical literature to identify factors that prognosticate survival in SLE-PH, and secondarily to evaluate the methodological rigor of these studies using a validated index.</p></sec>
<sec id="sec2-0961203311429815" sec-type="materials|methods"><title>Material and methods</title>
<sec id="sec3-0961203311429815"><title>Data sources and searches</title>
<p>One investigator (SC) and an information specialist (RF) through the University Health Network (UHN) Library Services independently performed the literature search. Ovid Medline (1950 to December week 5 2009), EMBASE (1980 to 2010 week 2), Cochrane Central Registry of Controlled Trials (inception to fourth quarter 2009), and CINAHL (1980 to 2009) were searched. The search strategy started with the inception date of each database to the beginning of 2010. The following keywords with mapping of term to subject heading were used in the database search: (systemic lupus erythematosus or SLE or libman disease) and (pulmonary arterial hypertension or Ayerza disease) and (prognosis or cohort studies or morbidity or mortality or survival analysis or statistical model or prediction or course or diagnosis or cohort or death or outcome or follow up or physical disease by body function or general aspect of disease or survival rate or survival time). The University Health Network prognosis filter for Medline and McKibbon prognosis filter for Elton B. Stephens Company were used. These are predefined and pretested search queries designed to retrieve selections of records in specified biomedical bibliographic databases. The search was limited to human studies but not limited to English language. The results of the two independent searches were compared to ensure completeness (<xref ref-type="fig" rid="fig1-0961203311429815">Figure 1</xref>).
<fig id="fig1-0961203311429815" position="float"><label>Figure 1</label><caption><p>Flow diagram of search results. CTD: connective tissue disease, PAH: pulmonary arterial hypertension, SLE: systemic lupus erythematosus.</p></caption><graphic xlink:href="10.1177_0961203311429815-fig1.tif"/></fig></p></sec>
<sec id="sec4-0961203311429815"><title>Study selection</title>
<p>Titles and abstracts were screened to identify studies that described prognostic factors in SLE patients with PH. Eligible studies were required to report factors associated with death or survival as an outcome. Studies were ineligible if they were animal studies or review articles, did not describe prognostic factors or did not report death/survival as an outcome. The reference list of selected articles was hand searched for additional relevant publications.</p></sec>
<sec id="sec5-0961203311429815"><title>Data abstraction</title>
<p>Two reviewers (SC and VC) independently abstracted the following data onto standardized forms: study design (case report, case series, retrospective or prospective cohort, case–control or randomized trial), sample size, prognostic factors, and measure of survival. All disagreements were resolved by consensus.</p></sec>
<sec id="sec6-0961203311429815"><title>Methodological quality</title>
<p>The methodological quality of the identified prognostic studies was evaluated using a validated index.<sup><xref ref-type="bibr" rid="bibr29-0961203311429815">29</xref></sup> Studies were evaluated on their reporting of study participants, study attrition, prognostic factor measurement, outcome measurement, confounding measurement, and analysis. Domains were evaluated by two raters (SC and VC) and discrepancies were resolved by consensus.</p></sec></sec>
<sec id="sec7-0961203311429815" sec-type="results"><title>Results</title>
<sec id="sec8-0961203311429815"><title>Search results</title>
<p>Three hundred and seventy-five citations were identified; however, screening of titles and abstracts resulted in the exclusion of 335 citations, leaving 40 articles for full review. Screening the full articles identified 23 articles that had prognostic factors for SLE-PH patients. Articles were excluded because they were review articles or involved patients with rheumatic diseases other than SLE. One article could not be obtained because none of the resource sharing partners held this title, including the National Library of Medicine and the National Research Council of Canada. Of the 23 citations obtained, one was a prospective cohort study, 10 were retrospective cohort studies, and 12 were case series/reports. No randomized controlled trials were identified.</p>
<p>In the study we were unable to obtain, Tegzova et al. report 100 SLE patients who were followed in one clinic over 3 years in the former Czechoslovakia.<sup><xref ref-type="bibr" rid="bibr30-0961203311429815">30</xref></sup> They identified 10 patients with SLE-PAH based on echocardiogram, and confirmed the presence of PAH in eight patients by right heart catheterization. These patients were females of child bearing age. Four died due to heart failure, a mean of 1.3 years after PAH detection. Three had a PAP greater than 50 mmHg and had antiphospholipid antibodies, and two had pulmonary embolism. Autopsy demonstrated pulmonary arteriole vasculopathy with media thickening and plexiform lesions.</p></sec>
<sec id="sec9-0961203311429815"><title>Factors associated with decreased survival in SLE-PH (<xref ref-type="table" rid="table1-0961203311429815">Table 1</xref>)</title>
<sec id="sec10-0961203311429815"><title>Elevated pulmonary artery systolic pressure (PASP)</title>
<p>
<table-wrap id="table1-0961203311429815" position="float"><label>Table 1</label><caption><p>Factors associated with survival in SLE-PH</p></caption>
<graphic alternate-form-of="table1-0961203311429815" xlink:href="10.1177_0961203311429815-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Factors</th>
<th>Study design</th>
<th>Sample size</th>
<th>Duration between PH diagnosis and death</th>
<th>Pulmonary artery pressure (mmHg)</th>
<th>References</th></tr></thead>
<tbody align="left">
<tr>
<td rowspan="3">Elevated pulmonary artery systolic pressure</td>
<td>Retrospective cohort</td>
<td><italic>n</italic> = 4/18</td>
<td>0–52 months</td>
<td>sPAP 80–90</td>
<td>Li 1999<sup><xref ref-type="bibr" rid="bibr5-0961203311429815">5</xref></sup></td></tr>
<tr>
<td>Retrospective cohort</td>
<td><italic>n</italic> = 6</td>
<td>0.5–15 months</td>
<td>sPAP 69–100</td>
<td>Kim 1999<sup><xref ref-type="bibr" rid="bibr2-0961203311429815">2</xref></sup><sup><xref ref-type="bibr" rid="bibr7-0961203311429815">7</xref></sup></td></tr>
<tr>
<td>Retrospective cohort</td>
<td><italic>n</italic> = 1/6</td>
<td>3 years</td>
<td>RVSP 91</td>
<td>Chen 2006<sup><xref ref-type="bibr" rid="bibr1-0961203311429815">1</xref></sup><sup><xref ref-type="bibr" rid="bibr3-0961203311429815">3</xref></sup></td></tr>
<tr>
<td>Infection</td>
<td>Retrospective cohort</td>
<td><italic>n</italic> = 3/20 died</td>
<td>10 months</td>
<td>Not stated</td>
<td>Chung 2006<sup><xref ref-type="bibr" rid="bibr3-0961203311429815">3</xref></sup></td></tr>
<tr>
<td rowspan="6">Plexiform lesion</td>
<td>Case series</td>
<td><italic>n</italic> = 2</td>
<td>19–21 months</td>
<td>sPAP 102–115</td>
<td>Goldman 1994<sup><xref ref-type="bibr" rid="bibr3-0961203311429815">3</xref></sup><sup><xref ref-type="bibr" rid="bibr4-0961203311429815">4</xref></sup></td></tr>
<tr>
<td>Retrospective cohort</td>
<td><italic>n</italic> = 2/4</td>
<td>0–52 months</td>
<td>mPAP 75</td>
<td>Li 1999<sup><xref ref-type="bibr" rid="bibr5-0961203311429815">5</xref></sup></td></tr>
<tr>
<td>Case series</td>
<td><italic>n</italic> = 2</td>
<td>48 h</td>
<td>sPAP 80–90</td>
<td>McMillan 2002<sup><xref ref-type="bibr" rid="bibr3-0961203311429815">3</xref></sup><sup><xref ref-type="bibr" rid="bibr5-0961203311429815">5</xref></sup></td></tr>
<tr>
<td>Case report</td>
<td><italic>n</italic> = 1/2</td>
<td>11 years</td>
<td>mPAP 70–80</td>
<td>Schwartzberg</td></tr>
<tr>
<td rowspan="2"/>
<td rowspan="2"/>
<td rowspan="2"/>
<td>sPAP 68</td>
<td rowspan="2">1984<sup><xref ref-type="bibr" rid="bibr3-0961203311429815">3</xref></sup><sup><xref ref-type="bibr" rid="bibr6-0961203311429815">6</xref></sup></td></tr>
<tr>
<td>mPAP 52</td></tr>
<tr>
<td rowspan="2">Pregnancy</td>
<td>Case series</td>
<td><italic>n</italic> = 2/3</td>
<td>48 h</td>
<td>mPAP 70–80</td>
<td>McMillan 2002<sup><xref ref-type="bibr" rid="bibr3-0961203311429815">3</xref></sup><sup><xref ref-type="bibr" rid="bibr5-0961203311429815">5</xref></sup></td></tr>
<tr>
<td>Case report</td>
<td><italic>n</italic> = 1</td>
<td>48 h</td>
<td>sPAP 98</td>
<td>Rubin 1995<sup><xref ref-type="bibr" rid="bibr1-0961203311429815">1</xref></sup><sup><xref ref-type="bibr" rid="bibr9-0961203311429815">9</xref></sup></td></tr>
<tr>
<td rowspan="3">Pulmonary vasculitis</td>
<td>Case report</td>
<td><italic>n</italic> = 1</td>
<td>48 h</td>
<td>sPAP 98</td>
<td>Rubin 1995<sup><xref ref-type="bibr" rid="bibr1-0961203311429815">1</xref></sup><sup><xref ref-type="bibr" rid="bibr9-0961203311429815">9</xref></sup></td></tr>
<tr>
<td>Case report</td>
<td><italic>n</italic> = 1</td>
<td>21 months</td>
<td>sPAP 102–115</td>
<td>Goldman 1994<sup><xref ref-type="bibr" rid="bibr3-0961203311429815">3</xref></sup><sup><xref ref-type="bibr" rid="bibr4-0961203311429815">4</xref></sup></td></tr>
<tr>
<td/>
<td/>
<td/>
<td>mPAP 75</td>
<td/></tr>
<tr>
<td rowspan="3">Raynaud’s phenomenon</td>
<td>Retrospective cohort</td>
<td><italic>n</italic> = 5/5</td>
<td>Not stated</td>
<td>Not stated</td>
<td rowspan="2">Lavras Constallat 1995<sup><xref ref-type="bibr" rid="bibr1-0961203311429815">1</xref></sup><sup><xref ref-type="bibr" rid="bibr7-0961203311429815">7</xref></sup></td></tr>
<tr>
<td>Case series</td>
<td><italic>n</italic> = 2</td>
<td>Not stated</td>
<td>sPAP 55–76</td></tr>
<tr>
<td/>
<td/>
<td/>
<td>mPAP 45–57</td>
<td>Bautista 1992<sup><xref ref-type="bibr" rid="bibr31-0961203311429815">31</xref></sup></td></tr>
<tr>
<td>Thrombocytopenia</td>
<td>Case series</td>
<td><italic>n</italic> = 4/6</td>
<td>3–36 months</td>
<td>sPAP 77–125</td>
<td>Horn 2000<sup><xref ref-type="bibr" rid="bibr3-0961203311429815">3</xref></sup><sup><xref ref-type="bibr" rid="bibr7-0961203311429815">7</xref></sup></td></tr>
<tr>
<td rowspan="4">Thrombosis and anticardiolipin antibody</td>
<td>Retrospective cohort</td>
<td><italic>n</italic> = 3/11</td>
<td>Not stated</td>
<td>Not stated</td>
<td>Jiang 2002<sup><xref ref-type="bibr" rid="bibr33-0961203311429815">33</xref></sup></td></tr>
<tr>
<td>Case report</td>
<td><italic>n</italic> = 1</td>
<td>10 years</td>
<td>sPAP 100</td>
<td/></tr>
<tr>
<td rowspan="2">Case series</td>
<td rowspan="2"><italic>n</italic> = 2</td>
<td rowspan="2">Not stated</td>
<td>sPAP 55–76</td>
<td>Semeniuk 2001<sup><xref ref-type="bibr" rid="bibr32-0961203311429815">32</xref></sup></td></tr>
<tr>
<td>mPAP 45–57</td>
<td>Bautista 1992<sup><xref ref-type="bibr" rid="bibr31-0961203311429815">31</xref></sup></td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203311429815"><p>There is variability between studies in the method of reporting the pulmonary artery pressures. mPAP: mean pulmonary artery pressure, PAP: pulmonary artery pressure, PH: pulmonary hypertension, RVSP: right ventricular systolic pressure, SLE: systemic lupus erythematosus, sPAP: systolic pulmonary artery pressure.</p></fn></table-wrap-foot>
</table-wrap>
Three retrospective cohort studies found that an elevated pulmonary artery systolic pressure (PASP) was associated with a worse prognosis.<sup><xref ref-type="bibr" rid="bibr5-0961203311429815">5</xref>,<xref ref-type="bibr" rid="bibr13-0961203311429815">13</xref>,<xref ref-type="bibr" rid="bibr27-0961203311429815">27</xref></sup> In one study,<sup><xref ref-type="bibr" rid="bibr5-0961203311429815">5</xref></sup> PASP was higher among those who died (<italic>p</italic> = 0.017). PASP was also higher among those who had never received immunosuppressive therapy prior to the diagnosis of PAH, and there was a trend among those who were symptomatic (<italic>p</italic> = 0.07). The probability of survival for SLE patients with PH compared with SLE controls was 86% compared with 90% at 5 years and 68% compared with 83% at 10 years (<italic>p</italic> = 0.23). Among those still living, there was a 21% mean reduction in pulmonary pressure over time due to immunosuppressive agents, antimalarials, diltiazem and warfarin. Hydroxychloroquine was the only treatment associated with a significant reduction in PASP in eight patients (<italic>p</italic> = 0.01). In another retrospective study of 19 connective tissue disease patients with PH, six were SLE-PH patients.<sup><xref ref-type="bibr" rid="bibr13-0961203311429815">13</xref></sup> Of these six people, one died with an elevated right ventricular systolic pressure (RVSP) compared with the other five SLE-PH patients who survived. Of the 19 connective tissue disease patients, their mortality rate was 57.1% for those with a RVSP ≥80 mmHg versus 8.3% for those with an RVSP &lt;80 mmHg. A third study of 43 SLE patients who died in Korea found that PH was the third most common cause of death (15%).<sup><xref ref-type="bibr" rid="bibr27-0961203311429815">27</xref></sup> These six SLE-PH patients had elevated pulmonary pressures (70–100 mmHg) at diagnosis with a short interval to death. The median time from diagnosis of SLE to PAH was 53.5 months versus 2.5 months from diagnosis of PAH to death (<italic>p</italic> = 0.01).</p></sec>
<sec id="sec11-0961203311429815"><title>Raynaud’s phenomenon (RP)</title>
<p>RP was associated with worse survival in two studies. A retrospective cohort review of 273 SLE patients compared those with RP (<italic>n</italic> = 123) with those without RP (<italic>n</italic> = 268). They observed that all five patients with SLE and PH had RP, and all five patients died.<sup><xref ref-type="bibr" rid="bibr17-0961203311429815">17</xref></sup> Another case series reported two patients with SLE and PAH with RP, who both died.<sup><xref ref-type="bibr" rid="bibr31-0961203311429815">31</xref></sup></p></sec>
<sec id="sec12-0961203311429815"><title>Antiphospholipid antibodies (APLA) and thrombosis</title>
<p>In one case report, a male with SLE developed PH associated with anticardiolipin antibodies, developed a pulmonary embolism 10 years after diagnosis and died.<sup><xref ref-type="bibr" rid="bibr32-0961203311429815">32</xref></sup> In another case series, two young women with SLE and PH had anticardiolipin antibodies and died.<sup><xref ref-type="bibr" rid="bibr31-0961203311429815">31</xref></sup> A retrospective cohort study of 11 patients with SLE and PH found that all 11 had pulmonary embolism and three patients died despite prednisone, immunosuppression and anticoagulant therapy.<sup><xref ref-type="bibr" rid="bibr33-0961203311429815">33</xref></sup> The presence of antiphospholipid antibodies was not described.</p></sec>
<sec id="sec13-0961203311429815"><title>Plexiform lesions</title>
<p>Plexiform lesions were seen microscopically on the muscular portion of pulmonary arteries in a case series of two patients with SLE associated PH.<sup><xref ref-type="bibr" rid="bibr34-0961203311429815">34</xref></sup> Two SLE patients who died of pulmonary hypertension in pregnancy also had plexiform lesions.<sup><xref ref-type="bibr" rid="bibr35-0961203311429815">35</xref></sup> One patient with pulmonary hypertension had an open lung biopsy that revealed plexiform lesions, and symptoms of SLE developed.<sup><xref ref-type="bibr" rid="bibr36-0961203311429815">36</xref></sup> A retrospective cohort of 18 SLE-PH patients had four deaths, and two post-mortem findings were available. Both had plexiform lesions on pathology.<sup><xref ref-type="bibr" rid="bibr5-0961203311429815">5</xref></sup> These were described as muscularization of arterioles, fibroblastic proliferation of the intima, and angiomatoid change of pulmonary vasculature without fibrinoid necrosis.</p></sec>
<sec id="sec14-0961203311429815"><title>Thrombocytopenia</title>
<p>In a case series of six patients with SLE-PH treated with epoprostenol, four had life-threatening thrombocytopenia despite their lupus being quiescent.<sup><xref ref-type="bibr" rid="bibr22-0961203311429815">22</xref></sup> These patients had no other manifestations of active lupus. These four patients died despite aggressive steroid therapy, intravenous immunoglobulin, and epoprostenol therapy. The two patients who survived did not have thrombocytopenia and continued to be treated with epoprostenol therapy for their PH.</p></sec>
<sec id="sec15-0961203311429815"><title>Infection</title>
<p>A single center retrospective cohort study of 20 SLE PAH patients observed a median survival of 13 months and 1, 3 and 5-year survival rates of 50%, 45%, and 17%.<sup><xref ref-type="bibr" rid="bibr3-0961203311429815">3</xref></sup> Three of the 12 deceased patients died from infection. The types of infection were not described.</p></sec>
<sec id="sec16-0961203311429815"><title>Pregnancy</title>
<p>One case report describes a pregnant SLE patient who developed PH and died of severe pulmonary hypertension.<sup><xref ref-type="bibr" rid="bibr35-0961203311429815">35</xref></sup> Autopsy showed no active SLE or pulmonary emboli, but did find pulmonary artery intimal thickening, medial hypertrophy, fibrosis and marked plexiform lesions.<sup><xref ref-type="bibr" rid="bibr35-0961203311429815">35</xref></sup> Another case report describes a pregnant SLE patient who developed PH and had a rapidly fatal course. Autopsy demonstrated pulmonary vasculitis.<sup><xref ref-type="bibr" rid="bibr19-0961203311429815">19</xref></sup></p></sec>
<sec id="sec17-0961203311429815"><title>Oral contraceptive pill (OCP)</title>
<p>One case report describes a woman with SLE who developed acute and rapidly progressive PH 8 months after starting the OCP.<sup><xref ref-type="bibr" rid="bibr38-0961203311429815">38</xref></sup> The authors hypothesize that estrogens may exacerbate the SLE disease, based on a previous study that showed that half the patients with SLE who receive estrogen experience an exacerbation of their disease within 3 months.<sup><xref ref-type="bibr" rid="bibr39-0961203311429815">39</xref></sup></p></sec>
<sec id="sec18-0961203311429815"><title>Pulmonary vasculitis</title>
<p>Two case reports of SLE patients with rapidly fatal PH were found to have pulmonary vasculitis. One case was seen in a pregnant SLE patient with no known history of PH.<sup><xref ref-type="bibr" rid="bibr19-0961203311429815">19</xref></sup> Within 48 h of delivering she developed shortness of breath and hemodynamic collapse. She had no other symptoms of SLE including arthritis, malar rash, or acrocyanosis. Her autopsy demonstrated acute inflammation of the large and medium sized pulmonary arteries as well as focal fibrinoid necrosis.<sup><xref ref-type="bibr" rid="bibr19-0961203311429815">19</xref></sup> Another case report described a 22-year-old woman who died with severe PH.<sup><xref ref-type="bibr" rid="bibr34-0961203311429815">34</xref></sup> Microscopically there were several large muscular arteries exhibiting necrotizing arteritis and smaller arteries with intimal proliferation and fibrosis. Other SLE manifestations were not noted.</p></sec></sec>
<sec id="sec19-0961203311429815"><title>Factors not associated with worse survival in SLE-PAH (<xref ref-type="table" rid="table2-0961203311429815">Table 2</xref>)</title>
<sec id="sec20-0961203311429815"><title>SLE disease activity</title>
<p>
<table-wrap id="table2-0961203311429815" position="float"><label>Table 2</label><caption><p>Factors not associated with survival in SLE-PH</p></caption>
<graphic alternate-form-of="table2-0961203311429815" xlink:href="10.1177_0961203311429815-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Factors</th>
<th>Study design</th>
<th>Sample size or data</th>
<th>Duration between PH diagnosis and death</th>
<th>Pulmonary artery pressure (mmHg)</th>
<th>References</th></tr></thead>
<tbody align="left">
<tr>
<td rowspan="11"><bold>SLE disease activity</bold></td>
<td>Case report</td>
<td><italic>n</italic> = 1</td>
<td>17 months</td>
<td>sPAP 82</td>
<td>Kawamura 2002<sup><xref ref-type="bibr" rid="bibr40-0961203311429815">40</xref></sup></td></tr>
<tr>
<td>Case report</td>
<td><italic>n</italic> = 1</td>
<td>1 month</td>
<td>sPAP 108</td>
<td>Ebrahim 1999<sup><xref ref-type="bibr" rid="bibr44-0961203311429815">44</xref></sup></td></tr>
<tr>
<td rowspan="2">Retrospective cohort</td>
<td rowspan="2"><italic>n</italic> = 6</td>
<td>0.5–15 months</td>
<td>sPAP 69–100</td>
<td>Kim 1999<sup><xref ref-type="bibr" rid="bibr2-0961203311429815">2</xref></sup><sup><xref ref-type="bibr" rid="bibr7-0961203311429815">7</xref></sup></td></tr>
<tr>
<td>5 months</td>
<td>sPAP 87</td>
<td/></tr>
<tr>
<td>Case report</td>
<td><italic>n</italic> = 1</td>
<td>Not stated</td>
<td>mPAP 40</td>
<td>Koyama 1996<sup><xref ref-type="bibr" rid="bibr41-0961203311429815">41</xref></sup></td></tr>
<tr>
<td>Case report</td>
<td><italic>n</italic> = 1</td>
<td>11 years</td>
<td>sPAP 80</td>
<td>Matsumoto 1991<sup><xref ref-type="bibr" rid="bibr43-0961203311429815">43</xref></sup></td></tr>
<tr>
<td>Case report</td>
<td><italic>n</italic> = 1/2</td>
<td>23 months</td>
<td>mPAP 44</td>
<td>Schwartzberg 1984<sup><xref ref-type="bibr" rid="bibr3-0961203311429815">3</xref></sup><sup><xref ref-type="bibr" rid="bibr6-0961203311429815">6</xref></sup></td></tr>
<tr>
<td>Case report</td>
<td><italic>n</italic> = 1</td>
<td/>
<td>sPAP 68</td>
<td>Marchesoni 1983<sup><xref ref-type="bibr" rid="bibr42-0961203311429815">42</xref></sup></td></tr>
<tr>
<td/>
<td/>
<td/>
<td>mPAP 52</td>
<td/></tr>
<tr>
<td/>
<td/>
<td/>
<td>sPAP 85</td>
<td/></tr>
<tr>
<td/>
<td/>
<td/>
<td>mPAP 55</td>
<td/></tr>
<tr>
<td rowspan="3"><bold>Nephritis</bold></td>
<td rowspan="3">Retrospective cohort</td>
<td>50% versus 88.2%,</td>
<td rowspan="3">0.5–15 months</td>
<td rowspan="3">sPAP 69–100</td>
<td rowspan="3">Kim 1999<sup><xref ref-type="bibr" rid="bibr2-0961203311429815">2</xref></sup><sup><xref ref-type="bibr" rid="bibr7-0961203311429815">7</xref></sup></td></tr>
<tr>
<td><italic>p</italic> = 0.023</td></tr>
<tr>
<td><italic>n</italic> = 6 vs. 32</td></tr>
<tr>
<td rowspan="3"><bold>CNS disease</bold></td>
<td rowspan="3">Retrospective cohort</td>
<td>16.7% versus 61.8%,</td>
<td rowspan="3">0.5–15 months</td>
<td rowspan="3">sPAP 69–100</td>
<td rowspan="3">Kim 1999<sup><xref ref-type="bibr" rid="bibr2-0961203311429815">2</xref></sup><sup><xref ref-type="bibr" rid="bibr7-0961203311429815">7</xref></sup></td></tr>
<tr>
<td><italic>p</italic> = 0.041,</td></tr>
<tr>
<td><italic>n</italic> = 6 vs. 32</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0961203311429815"><p>All <italic>p</italic> values are from original articles. There is variability between studies in the method of reporting the pulmonary artery pressures. CNS: central nervous system, mPAP: mean pulmonary artery pressure, PAP: pulmonary artery pressure, PH: pulmonary hypertension, RVSP: right ventricular systolic pressure, SLE: systemic lupus erythematosus, sPAP: systolic pulmonary artery pressure.</p></fn></table-wrap-foot>
</table-wrap>
Lupus activity was not associated with SLE-PH survival in five case reports.<sup><xref ref-type="bibr" rid="bibr40-0961203311429815">40</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr44-0961203311429815">44</xref></sup> These patients had minimal or quiescent disease and normal complement or anti-double-stranded DNA (anti-dsDNA). In one retrospective cohort of mortality in SLE,<sup><xref ref-type="bibr" rid="bibr27-0961203311429815">27</xref></sup> 43 deaths occurred, and in six cases PH was the cause of death. These six patients had normal complement levels and anti-dsDNA antibody titers and had no clinical evidence of disease except for the respiratory symptoms. These six patients also had less nephritis (50% versus 88.2%, <italic>p</italic> = 0.023) and less central nervous system disease (16.7% versus 61.8%, <italic>p</italic> = 0.041) compared with those who died of other causes.</p></sec></sec></sec>
<sec id="sec21-0961203311429815"><title>Methodological quality assessment</title>
<p>Methodological quality assessment was performed on the 23 identified articles by two independent raters (SC and VC). Any disagreements were resolved through consensus. For each study, the reporting of study participants, study attrition, prognostic factor measurement, outcome measurement, confounding measurement, and analysis were evaluated. All the studies were case studies or small cohort studies. None were randomized or controlled trials. Four studies were not in the English language, so we could not judge the methodological quality of these studies. The results are summarized in <xref ref-type="table" rid="table3-0961203311429815">Table 3</xref>.
<table-wrap id="table3-0961203311429815" position="float"><label>Table 3</label><caption><p>Quality assessment of prognostic studies</p></caption>
<graphic alternate-form-of="table3-0961203311429815" xlink:href="10.1177_0961203311429815-table3a.tif"/>
<graphic alternate-form-of="table3-0961203311429815" xlink:href="10.1177_0961203311429815-table3b.tif"/>
<table frame="hsides"><thead align="left">
<tr><th><bold>Criteria/Ref #</bold></th>
<th>1<sup><xref ref-type="bibr" rid="bibr46-0961203311429815">46</xref></sup></th>
<th>2<sup><xref ref-type="bibr" rid="bibr3-0961203311429815">3</xref></sup></th>
<th>3<sup><xref ref-type="bibr" rid="bibr13-0961203311429815">13</xref></sup></th>
<th>4<sup><xref ref-type="bibr" rid="bibr35-0961203311429815">35</xref></sup></th>
<th>5<sup><xref ref-type="bibr" rid="bibr40-0961203311429815">40</xref></sup></th>
<th>6<sup><xref ref-type="bibr" rid="bibr37-0961203311429815">37</xref></sup></th>
<th>7<sup><xref ref-type="bibr" rid="bibr5-0961203311429815">5</xref></sup></th>
<th>8<sup><xref ref-type="bibr" rid="bibr27-0961203311429815">27</xref></sup></th>
<th>9<sup><xref ref-type="bibr" rid="bibr44-0961203311429815">44</xref></sup></th>
<th>10<sup><xref ref-type="bibr" rid="bibr41-0961203311429815">41</xref></sup></th>
<th>11<sup><xref ref-type="bibr" rid="bibr18-0961203311429815">18</xref></sup></th>
<th>12<sup><xref ref-type="bibr" rid="bibr19-0961203311429815">19</xref></sup></th>
<th>13<sup><xref ref-type="bibr" rid="bibr34-0961203311429815">34</xref></sup></th>
<th>14<sup><xref ref-type="bibr" rid="bibr10-0961203311429815">10</xref></sup></th>
<th>15<sup><xref ref-type="bibr" rid="bibr38-0961203311429815">38</xref></sup></th>
<th>16<sup><xref ref-type="bibr" rid="bibr47-0961203311429815">47</xref></sup></th>
<th>17<sup><xref ref-type="bibr" rid="bibr45-0961203311429815">45</xref></sup></th>
<th>18<sup><xref ref-type="bibr" rid="bibr42-0961203311429815">42</xref></sup></th>
<th>19<sup><xref ref-type="bibr" rid="bibr48-0961203311429815">48</xref></sup></th></tr></thead>
<tbody align="left">
<tr>
<td> Research questionclearly  clearly stated</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td></tr>
<tr>
<td><bold>Study participants</bold></td>
<td colspan="19"/></tr>
<tr>
<td> Source population  clearly defined</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td></tr>
<tr>
<td> Inclusion criteria  specified</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td></tr>
<tr>
<td> Exclusion criteria  specified</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td></tr>
<tr>
<td> Baseline comparability  of groups reported</td>
<td>N/A</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N/A</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N/A</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N/A</td>
<td>Y</td>
<td>N/A</td>
<td>N</td></tr>
<tr>
<td> Recruitment period  specified</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>N</td></tr>
<tr>
<td> Place of recruitment  specified</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td></tr>
<tr>
<td><bold>Study attrition</bold></td>
<td colspan="19"/></tr>
<tr>
<td> Participation rate  reported</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td></tr>
<tr>
<td> Follow-up reported,  explained and  reasonable</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>N</td></tr>
<tr>
<td> Lost to follow-up equal  in both groups</td>
<td>N/A</td>
<td>N/S</td>
<td>N/S</td>
<td>N/A</td>
<td>N/A</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/A</td>
<td>N/A</td>
<td>N/S</td>
<td>N/A</td>
<td>N/A</td>
<td>N/S</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td></tr>
<tr>
<td> Lost to follow-up  patients characterized</td>
<td>Y</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/S</td>
<td>N</td>
<td>N</td>
<td>N/A</td>
<td>N/A</td>
<td>N</td>
<td>N/A</td>
<td>N/A</td>
<td>N</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td></tr>
<tr>
<td> Lost to follow-up  patients significantly  different from study</td>
<td>N/S</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/A</td>
<td>N/A</td>
<td>N/S</td>
<td>N/A</td>
<td>N/A</td>
<td>N/S</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td></tr>
<tr>
<td colspan="19"><bold>Prognostic factor measurement</bold></td>
<td/></tr>
<tr>
<td> All aspects of the factor  measured</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td></tr>
<tr>
<td> Factor measured at  baseline and follow-up</td>
<td>Y</td>
<td>N/S</td>
<td>N</td>
<td>N/S</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N/S</td>
<td>N</td>
<td>N/S</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N/S</td></tr>
<tr>
<td> Regular follow-up  periods maintained</td>
<td>Y</td>
<td>N/S</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>Y</td>
<td>Y</td>
<td>N/S</td>
<td>Y</td>
<td>N</td>
<td>N/S</td>
<td>Y</td>
<td>Y</td>
<td>N/S</td>
<td>Y</td>
<td>N/S</td></tr>
<tr>
<td> Other factors measured</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td></tr>
<tr>
<td> Time zero specified</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>N</td></tr>
<tr>
<td> Cutoffs for continuous  variables specified</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td></tr>
<tr>
<td> Adequate proportion of  sample had complete  data for factor</td>
<td>Y</td>
<td>N/S</td>
<td>Y</td>
<td>Y</td>
<td>N/A</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N/A</td>
<td>N</td>
<td>N/S</td>
<td>N/A</td>
<td>N/A</td>
<td>N/S</td>
<td>N/A</td>
<td>N/S</td>
<td>N/S</td>
<td>N/A</td>
<td>N/S</td></tr>
<tr>
<td> Method and setting of  factor measurement the  same for all participants</td>
<td>Y</td>
<td>N</td>
<td>N/S</td>
<td>N/S</td>
<td>Y</td>
<td>N/S</td>
<td>Y</td>
<td>N/S</td>
<td>N/A</td>
<td>N</td>
<td>N</td>
<td>N/A</td>
<td>N/A</td>
<td>N</td>
<td>N/A</td>
<td>Y</td>
<td>N</td>
<td>N/A</td>
<td>Y</td></tr>
<tr>
<td> Methods used to  account for missing data</td>
<td>Y</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N</td>
<td>N/S</td>
<td>N/S</td>
<td>N</td>
<td>N</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N</td>
<td>N/S</td>
<td>N</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td></tr>
<tr>
<td colspan="20"><bold>Outcome measurement</bold></td></tr>
<tr>
<td> Duration of follow-up  adequate</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N/S</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>N/A</td></tr>
<tr>
<td> Outcome defined and  measurable</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td></tr>
<tr>
<td> Valid outcome</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td></tr>
<tr>
<td> Blinded outcome  assessment</td>
<td>N</td>
<td>N</td>
<td>N/S</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N/S</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td></tr>
<tr>
<td> Same data collection  used for all participants</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>N/S</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N/A</td>
<td>Y</td>
<td>N/S</td>
<td>N/S</td>
<td>N/A</td>
<td>N</td>
<td>N/A</td>
<td>N/A</td>
<td>N/S</td>
<td>N/A</td>
<td>Y</td></tr>
<tr>
<td> Methods to account for  missing confounder data</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>Y</td>
<td>N</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N</td>
<td>N/S</td>
<td>N</td>
<td>N</td>
<td>N/S</td>
<td>N</td>
<td>N/S</td></tr>
<tr>
<td colspan="20"><bold>Confounding measurement and account</bold></td></tr>
<tr>
<td> Confounding variables  defined</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>N</td>
<td>N</td></tr>
<tr>
<td> Adjustment for  confounders in analysis</td>
<td>N/A</td>
<td>Y</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N/A</td>
<td>N/S</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td></tr>
<tr>
<td> Confounding variables  measured, valid and  reliable</td>
<td>Y</td>
<td>N/S</td>
<td>N</td>
<td>N/S</td>
<td>N</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>Y</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N</td>
<td>N/S</td>
<td>N</td>
<td>N/S</td></tr>
<tr>
<td> Similar confounding  variable measurement in  all study participants</td>
<td>Y</td>
<td>Y</td>
<td>N/S</td>
<td>N/S</td>
<td>N/A</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/A</td>
<td>N</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N</td>
<td>N/A</td>
<td>N/A</td>
<td>Y</td>
<td>N/A</td>
<td>NS</td></tr>
<tr>
<td> Confounding variables  accounted for in  study design</td>
<td>Y</td>
<td>N/S</td>
<td>N/S</td>
<td>N</td>
<td>N</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N</td>
<td>N/S</td>
<td>N/S</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N/S</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N/S</td></tr>
<tr>
<td><bold>Analysis</bold></td>
<td colspan="19"/></tr>
<tr>
<td> Pre-planned sample size  with adequate power</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N/S</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N/S</td>
<td>N</td>
<td>N/S</td></tr>
<tr>
<td> Appropriate statistical  analysis</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>N/A</td>
<td>N/S</td>
<td>Y</td>
<td>N</td>
<td>N/A</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N</td>
<td>N/S</td>
<td>N/A</td>
<td>N/S</td>
<td>N/A</td>
<td>N/S</td></tr>
<tr>
<td> Verifiable results from  the data</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>N</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td></tr>
<tr>
<td> Appropriate strategy for  model building based on  conceptual framework</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td></tr>
<tr>
<td> Selected model is  adequate for study  design</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/A</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td>
<td>N/S</td></tr>
<tr>
<td> Selective reporting  of results</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N/S</td>
<td>Y</td>
<td>N/S</td>
<td>N/S</td>
<td>Y</td>
<td>Y</td>
<td>N/S</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td>
<td>Y</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0961203311429815"><p>N: no, N/A: not applicable, N/S: not stated, Y: yes.</p></fn>
<fn id="table-fn4-0961203311429815"><p>Non-English papers were excluded from the quality assessment table.<sup><xref ref-type="bibr" rid="bibr11-0961203311429815">11</xref>,<xref ref-type="bibr" rid="bibr31-0961203311429815">31</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr33-0961203311429815">33</xref>,<xref ref-type="bibr" rid="bibr43-0961203311429815">43</xref>,<xref ref-type="bibr" rid="bibr49-0961203311429815">49</xref></sup></p></fn></table-wrap-foot>
</table-wrap></p></sec>
<sec id="sec22-0961203311429815"><title>Discussion</title>
<p>Pulmonary hypertension is a significant cause of mortality among patients with lupus. Patients can present with PH at diagnosis or it can occur suddenly during the course of their disease. They can have a steady downhill progression despite therapy, with death often occurring within 2 years of PH diagnosis. Progressive cardiac failure, sudden arrhythmia and cardiac arrest are common causes of death.<sup><xref ref-type="bibr" rid="bibr2-0961203311429815">2</xref>,<xref ref-type="bibr" rid="bibr3-0961203311429815">3</xref></sup> In this systematic review, we identified several factors which are associated with worse survival in SLE patients with PH.</p>
<p>An elevated pulmonary arterial systolic pressure was associated with worse prognosis in SLE patients. Three retrospective cohort studies found that pulmonary artery pressures were higher in those who died, with pressures &gt;70–80 mmHg associated with mortality.<sup><xref ref-type="bibr" rid="bibr5-0961203311429815">5</xref>,<xref ref-type="bibr" rid="bibr13-0961203311429815">13</xref>,<xref ref-type="bibr" rid="bibr27-0961203311429815">27</xref></sup> Patients with a higher pulmonary artery pressure at diagnosis were associated with a short interval from diagnosis to death, of 2.5 months.<sup><xref ref-type="bibr" rid="bibr27-0961203311429815">27</xref></sup> This is similar to scleroderma-associated PH<sup><xref ref-type="bibr" rid="bibr50-0961203311429815">50</xref></sup> and IPAH,<sup><xref ref-type="bibr" rid="bibr51-0961203311429815">51</xref></sup> in which abnormal PAP is a poor prognostic factor. This association is supported by plausibility (there is a credible mechanism to explain the association), coherence (the association is consistent with the natural history of the disease), consistency (the relationship was independently demonstrated by different groups of investigators),<sup><xref ref-type="bibr" rid="bibr5-0961203311429815">5</xref>,<xref ref-type="bibr" rid="bibr13-0961203311429815">13</xref>,<xref ref-type="bibr" rid="bibr27-0961203311429815">27</xref></sup> and biological gradient (increasing PAP is associated with a decreasing survival time).<sup><xref ref-type="bibr" rid="bibr27-0961203311429815">27</xref></sup> Aggressive treatment is warranted in SLE patients with elevated pulmonary pressures.</p>
<p>Post-mortem studies have identified plexiform lesions in the pulmonary arteries of some SLE patients who died with PH.<sup><xref ref-type="bibr" rid="bibr5-0961203311429815">5</xref>,<xref ref-type="bibr" rid="bibr34-0961203311429815">34</xref>,<xref ref-type="bibr" rid="bibr35-0961203311429815">35</xref>,<xref ref-type="bibr" rid="bibr52-0961203311429815">52</xref></sup> Plexiform lesions have been reported in an open-lung biopsy of a patient who was initially diagnosed as having IPAH, but who subsequently developed SLE.<sup><xref ref-type="bibr" rid="bibr36-0961203311429815">36</xref></sup> These lesions are seen in IPAH,<sup><xref ref-type="bibr" rid="bibr5-0961203311429815">5</xref></sup> and are associated with a poor prognosis, with a survival of only 50%, 35%, and 20% at 6 months, 1 year and 2 years.<sup><xref ref-type="bibr" rid="bibr53-0961203311429815">53</xref></sup> They have not been associated with long-standing pulmonary hypertension. Plexiform lesions are composed of a complex network of small blood vessels and proliferation of myofibroblasts within a dilated pulmonary arterial segment with partially disrupted media.<sup><xref ref-type="bibr" rid="bibr53-0961203311429815">53</xref></sup> Plexogenic disease has been associated with pulmonary pressures as high as systemic levels of blood pressure.<sup><xref ref-type="bibr" rid="bibr34-0961203311429815">34</xref></sup> It is hypothesized that plexiform lesions are formed from immune deposition in pulmonary arteries. However, these lesions are not consistently observed, and further studies are needed to investigate their true significance.</p>
<p>Although uncommon and classically not seen,<sup><xref ref-type="bibr" rid="bibr18-0961203311429815">18</xref></sup> the presence of pulmonary vasculitis may be an ominous prognostic sign. Our systematic review yielded two case reports of SLE patients with rapidly fatal PH who were found to have pulmonary vasculitis.<sup><xref ref-type="bibr" rid="bibr19-0961203311429815">19</xref>,<xref ref-type="bibr" rid="bibr34-0961203311429815">34</xref></sup> Leukocytoclastic vasculitis may occur in SLE but usually spares the muscular and large arteries and more classically presents as hemorrhagic alveolitis.<sup><xref ref-type="bibr" rid="bibr54-0961203311429815">54</xref></sup> Fibrinoid necrosis was observed in the SLE-PH reports. This is usually seen in polyarteritis nodosa, which classically spares the pulmonary vasculature. Pulmonary vasculitis may be another mechanism of pulmonary hypertension that leads to a worse prognosis.</p>
<p>RP has been shown to be associated with the occurrence of PH in SLE patients,<sup><xref ref-type="bibr" rid="bibr5-0961203311429815">5</xref></sup> and has been reported in as many as 75–80% of SLE-PH patients<sup><xref ref-type="bibr" rid="bibr6-0961203311429815">6</xref>,<xref ref-type="bibr" rid="bibr6-0961203311429815">6</xref>,<xref ref-type="bibr" rid="bibr13-0961203311429815">13</xref>,<xref ref-type="bibr" rid="bibr18-0961203311429815">18</xref>,<xref ref-type="bibr" rid="bibr55-0961203311429815">55</xref></sup> compared with 20–25% among those without PH.<sup><xref ref-type="bibr" rid="bibr56-0961203311429815">56</xref></sup> In this systematic review, one small retrospective cohort and several case reports demonstrated a worse prognosis in SLE-PH patients with RP.<sup><xref ref-type="bibr" rid="bibr17-0961203311429815">17</xref>,<xref ref-type="bibr" rid="bibr31-0961203311429815">31</xref></sup> The observed co-occurrence of PH and RP suggests that pulmonary arterial vasospasm may be involved in the pathogenesis of PH.<sup><xref ref-type="bibr" rid="bibr2-0961203311429815">2</xref>,<xref ref-type="bibr" rid="bibr21-0961203311429815">21</xref></sup> One group recommended that PH should be looked for routinely in lupus patients with RP.<sup><xref ref-type="bibr" rid="bibr17-0961203311429815">17</xref></sup> SLE with RP is usually a more mild disease; however, when associated with PH, it may lead to a grave prognosis.</p>
<p>Case reports suggest that the presence of APLA and thrombosis may lead to a worse prognosis in SLE patients with PAH. Asherson reported that 16 of 24 patients with SLE and PH had APLA, mostly at low titer.<sup><xref ref-type="bibr" rid="bibr2-0961203311429815">2</xref></sup> Four of these patients had APLA syndrome features, including three cases of deep vein thrombosis and one transient ischemic attack, and two of these patients died. Some studies have not supported this association between APLA and SLE-PH, as thrombosis was not commonly seen.<sup><xref ref-type="bibr" rid="bibr5-0961203311429815">5</xref>,<xref ref-type="bibr" rid="bibr18-0961203311429815">18</xref>,<xref ref-type="bibr" rid="bibr57-0961203311429815">57</xref></sup> In one study of 18 SLE-PH patients, seven had anticardiolipin antibodies, but none of them had features of APLA syndrome.<sup><xref ref-type="bibr" rid="bibr5-0961203311429815">5</xref></sup> Due to the varying methodological quality of these papers, it is difficult to make a firm conclusion that APLA and thrombosis may portend a worse prognosis in SLE-PH.</p>
<p>One case series of four patients who died of SLE-PH had life-threatening thrombocytopenia despite lupus being quiescent and maximal immunosuppressive therapy.<sup><xref ref-type="bibr" rid="bibr22-0961203311429815">22</xref></sup> The authors hypothesize that there may be localized platelet destruction in the pulmonary vascular bed. Other causes of thrombocytopenia, such as splenic sequestration, were not evident at autopsy. All patients were treated with epoprostenol, which improves symptoms, exercise tolerance and hemodynamics in patients with pulmonary hypertension associated with SLE. However, epoprostenol has been associated with thrombocytopenia, so the degree attributable to this drug is unclear. The authors suggest more frequent reassessment to optimize medical and/or surgical therapeutic options, including lung transplantation, before it is precluded due to progressive life-threatening thrombocytopenia. More studies are needed to elucidate the true association between thrombocytopenia and SLE-PH.</p>
<p>In one cohort of 20 SLE-PH patients, infection was found to be associated with worse survival.<sup><xref ref-type="bibr" rid="bibr3-0961203311429815">3</xref></sup> The types of infection were not described, so it is difficult to determine whether SLE-PH patients may be more susceptible to infection caused by SLE itself or due to immunosuppressant medications. Nine patients with SLE-PH were treated with immunosuppressant, typically cyclophosphamide, but there was no difference in survival between treatment and non-treatment groups.</p>
<p>Pregnancy was associated with a poor prognosis in SLE-PH. Weiss et al. published reports that pulmonary hypertension in pregnancy had a mortality of 56%.<sup><xref ref-type="bibr" rid="bibr58-0961203311429815">58</xref></sup> This highlights pulmonary hypertension as a significant cause of indirect maternal deaths, with the highest risk within 72 h postpartum. This may be due to the reduced vascular compliance with PH with the normal postpartum increase in pulmonary blood flow. It has been suggested that pregnant SLE patients with a history of pulmonary embolism, interstitial lung disease or suspicious symptoms be screened for pulmonary hypertension.<sup><xref ref-type="bibr" rid="bibr35-0961203311429815">35</xref></sup> Early diagnosis and early admission to hospital for individualized care may improve prognosis.<sup><xref ref-type="bibr" rid="bibr58-0961203311429815">58</xref></sup></p>
<p>In our systematic review, we found that SLE disease activity was not necessarily associated with worse pulmonary hypertension. We found five case reports and one retrospective cohort in which pulmonary hypertension worsened when other features of SLE, including clinical features and serological tests, were quiescent. Another small cohort study of five SLE patients found that the manifestations of pulmonary hypertension were seen in the absence of signs of active systemic disease in patients.<sup><xref ref-type="bibr" rid="bibr45-0961203311429815">45</xref></sup> There are several reasons why this may be the case. One hypothesis is that PH may be completely unrelated to other organ disease in SLE. There are studies which have shown that when other features of SLE were active, PH was quiescent.<sup><xref ref-type="bibr" rid="bibr59-0961203311429815">59</xref></sup> There was no relationship between activity of SLE assessed clinically and the development and progression of pulmonary hypertension.<sup><xref ref-type="bibr" rid="bibr45-0961203311429815">45</xref></sup> Another hypothesis is that early silent pulmonary vascular involvement may occur with insidious progression and delayed clinical manifestations.<sup><xref ref-type="bibr" rid="bibr45-0961203311429815">45</xref></sup> Other antibodies to ribonucleoprotein (anti-RNP)<sup><xref ref-type="bibr" rid="bibr10-0961203311429815">10</xref>,<xref ref-type="bibr" rid="bibr12-0961203311429815">12</xref>,<xref ref-type="bibr" rid="bibr13-0961203311429815">13</xref></sup> and endothelin-1<sup><xref ref-type="bibr" rid="bibr20-0961203311429815">20</xref></sup> have been associated with SLE-PH; however, they were not poor prognostic factors in our review of the literature. Another hypothesis is that current treatments for SLE disease activity may not be as effective for PH. Indeed, there are reports of SLE activity being suppressed using prednisolone, but PH persisting and the patients dying.<sup><xref ref-type="bibr" rid="bibr40-0961203311429815">40</xref>,<xref ref-type="bibr" rid="bibr43-0961203311429815">43</xref></sup> Another study showed no difference in survival whether patients were treated with immunosuppression or not.<sup><xref ref-type="bibr" rid="bibr3-0961203311429815">3</xref></sup> This is controversial, as some SLE-PH patients do respond to immunosuppression.<sup><xref ref-type="bibr" rid="bibr14-0961203311429815">14</xref></sup> There may be a variable response to immunosuppression depending on the course of the disease, and thus it is important to detect PH as early as possible.<sup><xref ref-type="bibr" rid="bibr45-0961203311429815">45</xref></sup> Since the development of PH is not necessarily related to the severity of the overall lupus activity, a high index of suspicion is required.</p>
<p>The methodological quality of the prognostic studies was variable. Studies were heterogeneous with regard to study location, study size, ruling out secondary causes, and treatment. Inclusion and exclusion criteria were not specified and study attrition was not characterized. There were differing criteria for diagnosing PH using clinical features, radiography, echocardiography or right heart catheterization. Attributes of prognostic factor and outcome measurement were variably reported in all studies. Erroneous attribution of an association and bias could result from these deficiencies, thus limiting the validity and generalizability of these results.</p>
<p>There are some data evaluating the role of immunosuppressive therapy in SLE-PH. Small observational studies have reported improvement with immunosuppressive therapy,<sup><xref ref-type="bibr" rid="bibr14-0961203311429815">14</xref>,<xref ref-type="bibr" rid="bibr60-0961203311429815">60</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr62-0961203311429815">62</xref></sup> while others have reported clinical deterioration despite immunosuppressive therapy.<sup><xref ref-type="bibr" rid="bibr40-0961203311429815">40</xref>,<xref ref-type="bibr" rid="bibr63-0961203311429815">63</xref></sup> Recent observational studies suggest that a subset of SLE-PH patients will improve with immunosuppression. Sanchez et al. report that five of 13 (38%) SLE-PH patients treated with parenteral cyclophosphamide remained in functional class I or II with hemodynamic improvement after 1 year of therapy.<sup><xref ref-type="bibr" rid="bibr64-0961203311429815">64</xref>,<xref ref-type="bibr" rid="bibr65-0961203311429815">65</xref></sup> It has also been observed that some SLE-PH patients can be transitioned from prostaglandin therapy to oral PH specific treatment with continued improvement.<sup><xref ref-type="bibr" rid="bibr66-0961203311429815">66</xref></sup></p>
<p>Together, these findings suggest that SLE-PH is not one homogeneous condition, but a few distinct pathologically based subsets.<sup><xref ref-type="bibr" rid="bibr55-0961203311429815">55</xref>,<xref ref-type="bibr" rid="bibr67-0961203311429815">67</xref></sup> One subset may be those prone to thromboembolic disease. Features of this subset include the presence of the APLA syndrome, lupus anticoagulant/anticardiolipin antibodies, increased risk of developing thrombotic arteriopathy and pulmonary embolism. This subset of patients may benefit from concurrent anticoagulation. A second subset may be those with a pulmonary vasculopathy similar to SSc-PH. This vasculopathy manifests as non-inflammatory vascular remodeling, may contain plexiform lesions and may be associated with anti-RNP antibody. A third subset is those with an immune mediated vasculopathy leading to pulmonary vasculitis – inflammation of the pulmonary artery that may be reversible with immunosuppression. Indeed, some patients with SLE-PH have been found to have circulating anti-endothelial cell antibodies.<sup><xref ref-type="bibr" rid="bibr68-0961203311429815">68</xref></sup> Similarly, immune complex deposition (large amounts of IgG and C1q, and small amounts of IgM and C3 in the intimal and medial layers) has been described in the pulmonary vessels of SLE-PH patients<sup><xref ref-type="bibr" rid="bibr18-0961203311429815">18</xref></sup> (<xref ref-type="fig" rid="fig2-0961203311429815">Figure 2</xref>). These SLE-PH subsets appear to have a different temporal presentation (acute versus chronic; symptomatic versus indolent). The existence of SLE-PH subsets may explain the differential response to immunosuppressive therapy in observational studies. Correct identification of subsets may facilitate appropriate targeted therapy, allow treatment to start before irreversible vascular lesions occur,<sup><xref ref-type="bibr" rid="bibr69-0961203311429815">69</xref></sup> and identify those patients who require more aggressive therapy and those who can be stepped down to less aggressive therapy.<sup><xref ref-type="bibr" rid="bibr70-0961203311429815">70</xref></sup>
<fig id="fig2-0961203311429815" position="float"><label>Figure 2</label><caption><p>Possible subsets of SLE-PH and associated features. PH: pulmonary hypertension, RNP: ribonucleoprotein, SLE: systemic lupus erythematosus.</p></caption><graphic xlink:href="10.1177_0961203311429815-fig2.tif"/></fig></p>
<p>The main limitation of this systematic review is that all the studies were observational, uncontrolled, and collected retrospectively. Many studies were small case reports and case series. Due to the heterogeneity of the data, we were unable to perform a meta-analysis. As such, only inferences rather than firm conclusions can be made regarding prognostic factors. Our study is still of value as it synthesizes the current state of knowledge, provides data for hypothesis generation, and can guide future research directions. The methodological limitations of the previously published studies are not insurmountable, and additional research needs to be completed to properly evaluate the importance of these factors in SLE-PH. Studies using appropriate inclusion criteria (using consistent and well accepted criteria for the diagnosis of PH), appropriate sample size, rigorous follow-up and description of study attrition will significantly improve the quality of prognostic studies, and facilitate valid inferences.</p>
<p>In conclusion, our study summarizes factors that may be associated with worse prognosis in SLE-PH. The small sample sizes and variable methodological quality preclude definitive conclusions. This study provides the groundwork for further investigation in large cohorts.</p></sec>
</body>
<back>
<sec id="sec23-0961203311429815"><title>Conflict of interest</title>
<p>None declared.</p></sec>
<sec id="sec24-0961203311429815"><title>Funding</title>
<p>Dr Sindhu Johnson is supported by a Canadian Institutes of Health Research (CIHR) Clinician Scientist Award. Dr Vinod Chandran is supported by a CIHR clinical research initiative fellowship and the Krembil Foundation.</p></sec>
<ack><title>Acknowledgements</title>
<p>We would like to thank Dr Ye Sun and Queenie Qian Xu for helping to translate some articles.</p></ack>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203311429815"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asherson</surname><given-names>RA</given-names></name><name><surname>Hackett</surname><given-names>D</given-names></name><name><surname>Gharavi</surname><given-names>AE</given-names></name></person-group>. <article-title>Pulmonary hypertension in systemic lupus erythematosus: a report of three cases</article-title>. <source>J Rheumatol</source> <year>1986</year>; <volume>13</volume>: <fpage>416</fpage>–<lpage>420</lpage>.</citation></ref>
<ref id="bibr2-0961203311429815"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asherson</surname><given-names>RA</given-names></name><name><surname>Higenbottam</surname><given-names>TW</given-names></name><name><surname>Dinh Xuan</surname><given-names>AT</given-names></name><name><surname>Khamashta</surname><given-names>MA</given-names></name><name><surname>Hughes</surname><given-names>GR</given-names></name></person-group>. <article-title>Pulmonary hypertension in a lupus clinic: experience with twenty-four patients</article-title>. <source>J Rheumatol</source> <year>1990</year>; <volume>17</volume>: <fpage>1292</fpage>–<lpage>1298</lpage>.</citation></ref>
<ref id="bibr3-0961203311429815"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>SM</given-names></name><name><surname>Lee</surname><given-names>CK</given-names></name><name><surname>Lee</surname><given-names>EY</given-names></name><name><surname>Yoo</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>SD</given-names></name><name><surname>Moon</surname><given-names>HB</given-names></name></person-group>. <article-title>Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension</article-title>. <source>Clin Rheumatol</source> <year>2006</year>; <volume>25</volume>: <fpage>866</fpage>–<lpage>872</lpage>.</citation></ref>
<ref id="bibr4-0961203311429815"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quismorio</surname><given-names>FP</given-names><suffix>Jr</suffix></name></person-group>. <article-title>Clinical and pathologic features of lung involvement in systemic lupus erythematosus</article-title>. <source>Semin Resp Med</source> <year>1988</year>; <volume>9</volume>: <fpage>297</fpage>–<lpage>304</lpage>.</citation></ref>
<ref id="bibr5-0961203311429815"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>EK</given-names></name><name><surname>Tam</surname><given-names>LS</given-names></name></person-group>. <article-title>Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients</article-title>. <source>J Rheumatol</source> <year>1999</year>; <volume>26</volume>: <fpage>1923</fpage>–<lpage>1929</lpage>.</citation></ref>
<ref id="bibr6-0961203311429815"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Winslow</surname><given-names>TM</given-names></name><name><surname>Ossipov</surname><given-names>MA</given-names></name><name><surname>Fazio</surname><given-names>GP</given-names></name><name><surname>Simonson</surname><given-names>JS</given-names></name><name><surname>Redberg</surname><given-names>RF</given-names></name><name><surname>Schiller</surname><given-names>NB</given-names></name></person-group>. <article-title>Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus</article-title>. <source>Am Heart J</source> <year>1995</year>; <volume>129</volume>: <fpage>510</fpage>–<lpage>515</lpage>.</citation></ref>
<ref id="bibr7-0961203311429815"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>SR</given-names></name><name><surname>Granton</surname><given-names>JT</given-names></name></person-group>. <article-title>Scleroderma and systemic lupus associated pulmonary hypertension: How are they different?</article-title> <source>European Resp Rev</source> <year>2011</year>. <comment>[in press]</comment>.</citation></ref>
<ref id="bibr8-0961203311429815"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>SR</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name><name><surname>Ibanez</surname><given-names>D</given-names></name><name><surname>Granton</surname><given-names>JT</given-names></name></person-group>. <article-title>Pulmonary hypertension in systemic lupus</article-title>. <source>Lupus</source> <year>2004</year>; <volume>13</volume>: <fpage>506</fpage>–<lpage>509</lpage>.</citation></ref>
<ref id="bibr9-0961203311429815"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>MR</given-names></name><name><surname>Mathai</surname><given-names>SC</given-names></name><name><surname>Champion</surname><given-names>HC</given-names></name><etal/></person-group>. <article-title>Clinical differences between idiopathic and scleroderma-related pulmonary hypertension</article-title>. <source>Arthritis Rheum</source> <year>2006</year>; <volume>54</volume>: <fpage>3043</fpage>–<lpage>3050</lpage>.</citation></ref>
<ref id="bibr10-0961203311429815"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kasukawa</surname><given-names>R</given-names></name><name><surname>Nishimaki</surname><given-names>T</given-names></name><name><surname>Takagi</surname><given-names>T</given-names></name><name><surname>Miyawaki</surname><given-names>S</given-names></name><name><surname>Yokohari</surname><given-names>R</given-names></name><name><surname>Tsunematsu</surname><given-names>T</given-names></name></person-group>. <article-title>Pulmonary hypertension in connective tissue disease. Clinical analysis of sixty patients in multi-institutional study</article-title>. <source>Clin Rheumatol</source> <year>1990</year>; <volume>9</volume>: <fpage>56</fpage>–<lpage>62</lpage>.</citation></ref>
<ref id="bibr11-0961203311429815"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>YQ</given-names></name><name><surname>Zhang</surname><given-names>ZL</given-names></name><name><surname>Lu</surname><given-names>WX</given-names></name></person-group>. <article-title>[The clinical analysis of pulmonary arterial hypertension in connective tissue disease]</article-title>. <source>Chung Hua Nei Ko Tsa Chih</source> <year>2006</year>; <volume>45</volume>: <fpage>467</fpage>–<lpage>471</lpage>.</citation></ref>
<ref id="bibr12-0961203311429815"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roncoroni</surname><given-names>AJ</given-names></name><name><surname>Alvarez</surname><given-names>C</given-names></name><name><surname>Molinas</surname><given-names>F</given-names></name></person-group>. <article-title>Plexogenic arteriopathy associated with pulmonary vasculitis in systemic lupus erythematosus</article-title>. <source>Respiration</source> <year>1992</year>; <volume>59</volume>: <fpage>52</fpage>–<lpage>56</lpage>.</citation></ref>
<ref id="bibr13-0961203311429815"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CH</given-names></name><name><surname>Chen</surname><given-names>HA</given-names></name><name><surname>Wang</surname><given-names>HP</given-names></name><name><surname>Liao</surname><given-names>HT</given-names></name><name><surname>Chou</surname><given-names>CT</given-names></name><name><surname>Huang</surname><given-names>DF</given-names></name></person-group>. <article-title>Pulmonary arterial hypertension in autoimmune diseases: an analysis of 19 cases from a medical center in northern Taiwan</article-title>. <source>J Microbiol Immunol Infect</source> <year>2006</year>; <volume>39</volume>: <fpage>162</fpage>–<lpage>168</lpage>.</citation></ref>
<ref id="bibr14-0961203311429815"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Groen</surname><given-names>H</given-names></name><name><surname>Bootsma</surname><given-names>H</given-names></name><name><surname>Postma</surname><given-names>DS</given-names></name><name><surname>Kallenberg</surname><given-names>CG</given-names></name></person-group>. <article-title>Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide</article-title>. <source>J Rheumatol</source> <year>1993</year>; <volume>20</volume>: <fpage>1055</fpage>–<lpage>1057</lpage>.</citation></ref>
<ref id="bibr15-0961203311429815"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gurubhagavatula</surname><given-names>I</given-names></name><name><surname>Palevsky</surname><given-names>HI</given-names></name></person-group>. <article-title>Pulmonary hypertension in systemic autoimmune disease</article-title>. <source>Rheum Dis Clin North Am</source> <year>1997</year>; <volume>23</volume>: <fpage>365</fpage>–<lpage>394</lpage>.</citation></ref>
<ref id="bibr16-0961203311429815"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kanemoto</surname><given-names>N</given-names></name><name><surname>Gonda</surname><given-names>N</given-names></name><name><surname>Katsu</surname><given-names>M</given-names></name><name><surname>Fukuda</surname><given-names>J</given-names></name></person-group>. <article-title>Case report. Two cases of pulmonary hypertension with Raynaud’s phenomenon. Primary pulmonary hypertension and systemic lupus erythematosus</article-title>. <source>Jpn Heart J</source> <year>1975</year>; <volume>16</volume>: <fpage>354</fpage>–<lpage>360</lpage>.</citation></ref>
<ref id="bibr17-0961203311429815"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lavras Costallat</surname><given-names>LT</given-names></name><name><surname>Valente Coimbra</surname><given-names>AM</given-names></name></person-group>. <article-title>Raynaud’s phenomenon in systemic lupus erythematosus</article-title>. <source>Rev Rheum Engl Ed</source> <year>1995</year>; <volume>62</volume>: <fpage>349</fpage>–<lpage>353</lpage>.</citation></ref>
<ref id="bibr18-0961203311429815"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quismorio</surname><given-names>FP</given-names><suffix>Jr</suffix></name><name><surname>Sharma</surname><given-names>O</given-names></name><name><surname>Koss</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus</article-title>. <source>Semin Arthritis Rheum</source> <year>1984</year>; <volume>13</volume>: <fpage>349</fpage>–<lpage>359</lpage>.</citation></ref>
<ref id="bibr19-0961203311429815"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>LA</given-names></name><name><surname>Geran</surname><given-names>A</given-names></name><name><surname>Rose</surname><given-names>TH</given-names></name><name><surname>Cohen</surname><given-names>H</given-names></name></person-group>. <article-title>A fatal pulmonary complication of lupus in pregnancy</article-title>. <source>Arthritis Rheum</source> <year>1995</year>; <volume>38</volume>: <fpage>710</fpage>–<lpage>714</lpage>.</citation></ref>
<ref id="bibr20-0961203311429815"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>JY</given-names></name><name><surname>Chen</surname><given-names>SL</given-names></name><name><surname>Wu</surname><given-names>YX</given-names></name><etal/></person-group>. <article-title>Pulmonary hypertension in systemic lupus erythematosus</article-title>. <source>Rheumatol Int</source> <year>1999</year>; <volume>18</volume>: <fpage>147</fpage>–<lpage>151</lpage>.</citation></ref>
<ref id="bibr21-0961203311429815"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simonson</surname><given-names>JS</given-names></name><name><surname>Schiller</surname><given-names>NB</given-names></name><name><surname>Petri</surname><given-names>M</given-names></name><name><surname>Hellmann</surname><given-names>DB</given-names></name></person-group>. <article-title>Pulmonary hypertension in systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>1989</year>; <volume>16</volume>: <fpage>918</fpage>–<lpage>925</lpage>.</citation></ref>
<ref id="bibr22-0961203311429815"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robbins</surname><given-names>IM</given-names></name><name><surname>Gaine</surname><given-names>SP</given-names></name><name><surname>Schilz</surname><given-names>R</given-names></name><name><surname>Tapson</surname><given-names>VF</given-names></name><name><surname>Rubin</surname><given-names>LJ</given-names></name><name><surname>Loyd</surname><given-names>JE</given-names></name></person-group>. <article-title>Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus</article-title>. <source>Chest</source> <year>2000</year>; <volume>117</volume>: <fpage>14</fpage>–<lpage>18</lpage>.</citation></ref>
<ref id="bibr23-0961203311429815"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asherson</surname><given-names>RA</given-names></name><name><surname>Mackworth-Young</surname><given-names>CG</given-names></name><name><surname>Boey</surname><given-names>ML</given-names></name><etal/></person-group>. <article-title>Pulmonary hypertension in systemic lupus erythematosus</article-title>. <source>Br Med J (Clin Res Ed)</source> <year>1983</year>; <volume>287</volume>: <fpage>1024</fpage>–<lpage>1025</lpage>.</citation></ref>
<ref id="bibr24-0961203311429815"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boumpas</surname><given-names>DT</given-names></name><name><surname>Austin</surname><given-names>HA</given-names><suffix>3</suffix></name><name><surname>Fessler</surname><given-names>BJ</given-names><suffix>rd</suffix></name><name><surname>Balow</surname><given-names>JE</given-names></name><name><surname>Klippel</surname><given-names>JH</given-names></name><name><surname>Lockshin</surname><given-names>MD</given-names></name></person-group>. <article-title>Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease</article-title>. <source>Ann Intern Med</source> <year>1995</year>; <volume>122</volume>: <fpage>940</fpage>–<lpage>950</lpage>.</citation></ref>
<ref id="bibr25-0961203311429815"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horn</surname><given-names>CA</given-names></name></person-group>. <article-title>Pulmonary hypertension and autoimmune disease</article-title>. <source>Chest</source> <year>1993</year>; <volume>104</volume>: <fpage>279</fpage>–<lpage>280</lpage>.</citation></ref>
<ref id="bibr26-0961203311429815"><label>26.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fois</surname><given-names>E</given-names></name><name><surname>Le Guern</surname><given-names>V</given-names></name><name><surname>Dupuy</surname><given-names>A</given-names></name><name><surname>Humbert</surname><given-names>M</given-names></name><name><surname>Mouthon</surname><given-names>L</given-names></name><name><surname>Guillevin</surname><given-names>L</given-names></name></person-group>. <article-title>Noninvasive assessment of systolic pulmonary artery pressure in systemic lupus erythematosus: retrospective analysis of 93 patients</article-title>. <source>Clin Exp Rheumatol</source> <year>2010</year>; <volume>28</volume>: <fpage>836</fpage>–<lpage>841</lpage>.</citation></ref>
<ref id="bibr27-0961203311429815"><label>27.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>WU</given-names></name><name><surname>Min</surname><given-names>JK</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Cho</surname><given-names>CS</given-names></name><name><surname>Kim</surname><given-names>HY</given-names></name></person-group>. <article-title>Causes of death in Korean patients with systemic lupus erythematosus: a single center retrospective study</article-title>. <source>Clin Exp Rheumatol</source> <year>1999</year>; <volume>17</volume>: <fpage>539</fpage>–<lpage>545</lpage>.</citation></ref>
<ref id="bibr28-0961203311429815"><label>28.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Condliffe</surname><given-names>R</given-names></name><name><surname>Kiely</surname><given-names>DG</given-names></name><name><surname>Peacock</surname><given-names>AJ</given-names></name><etal/></person-group>. <article-title>Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era</article-title>. <source>Am J Respir Crit Care Med</source> <year>2009</year>; <volume>179</volume>: <fpage>151</fpage>–<lpage>157</lpage>.</citation></ref>
<ref id="bibr29-0961203311429815"><label>29.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hayden</surname><given-names>JA</given-names></name><name><surname>Cote</surname><given-names>P</given-names></name><name><surname>Bombardier</surname><given-names>C</given-names></name></person-group>. <article-title>Evaluation of the quality of prognosis studies in systematic reviews</article-title>. <source>Ann Intern Med</source> <year>2006</year>; <volume>144</volume>: <fpage>427</fpage>–<lpage>437</lpage>.</citation></ref>
<ref id="bibr30-0961203311429815"><label>30.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tegzova</surname><given-names>D</given-names></name><name><surname>Kamenik</surname><given-names>L</given-names></name><name><surname>Musilova</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>[The incidence and course of pulmonary hypertension in systemic lupus erythematosus patients. Three years follow up outcome]</article-title>. <source>Ceska Revmatologie</source> <year>2003</year>; <volume>11</volume>: <fpage>117</fpage>–<lpage>127</lpage>.</citation></ref>
<ref id="bibr31-0961203311429815"><label>31.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bautista</surname><given-names>GG</given-names></name><name><surname>Cabral</surname><given-names>A</given-names></name><name><surname>Achurra</surname><given-names>AF</given-names></name></person-group>. <article-title>[Pulmonary hypertension in generalized lupus erythematosus]</article-title>. <source>Rev Med Panama</source> <year>1992</year>; <volume>17</volume>: <fpage>23</fpage>–<lpage>27</lpage>.</citation></ref>
<ref id="bibr32-0961203311429815"><label>32.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Semeniuk</surname><given-names>GB</given-names></name><name><surname>Re</surname><given-names>R</given-names></name><name><surname>Freue</surname><given-names>RD</given-names></name></person-group>. <article-title>[Thrombosis of great pulmonary vessels causing severe pulmonary hypertension in systemic lupus erythematosus]</article-title>. <source>Medicina (B Aires)</source> <year>2001</year>; <volume>61</volume>: <fpage>319</fpage>–<lpage>321</lpage>.</citation></ref>
<ref id="bibr33-0961203311429815"><label>33.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>WB</given-names></name><name><surname>Tang</surname><given-names>FL</given-names></name></person-group>. <article-title>[Pulmonary thromboembolism in systemic lupus erythematosus: clinical analysis of 11 cases]</article-title>. <source>Chung Kuo I Hsueh Ko Hsueh Yuan Hsueh Pao</source> <year>2002</year>; <volume>24</volume>: <fpage>329</fpage>–<lpage>331</lpage>.</citation></ref>
<ref id="bibr34-0961203311429815"><label>34.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goldman</surname><given-names>J</given-names></name><name><surname>Edwards</surname><given-names>WD</given-names></name></person-group>. <article-title>Plexogenic pulmonary hypertension in systemic lupus erythematosus: Report of two cases and review of the literature</article-title>. <source>Cardiovasc Pathol</source> <year>1994</year>; <volume>3</volume>: <fpage>65</fpage>–<lpage>69</lpage>.</citation></ref>
<ref id="bibr35-0961203311429815"><label>35.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McMillan</surname><given-names>E</given-names></name><name><surname>Martin</surname><given-names>WL</given-names></name><name><surname>Waugh</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Management of pregnancy in women with pulmonary hypertension secondary to SLE and anti-phospholipid syndrome</article-title>. <source>Lupus</source> <year>2002</year>; <volume>11</volume>: <fpage>392</fpage>–<lpage>398</lpage>.</citation></ref>
<ref id="bibr36-0961203311429815"><label>36.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schwartzberg</surname><given-names>M</given-names></name><name><surname>Lieberman</surname><given-names>DH</given-names></name><name><surname>Getzoff</surname><given-names>B</given-names></name><name><surname>Ehrlich</surname><given-names>GE</given-names></name></person-group>. <article-title>Systemic lupus erythematosus and pulmonary vascular hypertension</article-title>. <source>Arch Intern Med</source> <year>1984</year>; <volume>144</volume>: <fpage>605</fpage>–<lpage>607</lpage>.</citation></ref>
<ref id="bibr37-0961203311429815"><label>37.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horn</surname><given-names>EM</given-names></name><name><surname>Barst</surname><given-names>RJ</given-names></name><name><surname>Poon</surname><given-names>M</given-names></name></person-group>. <article-title>Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus</article-title>. <source>Chest</source> <year>2000</year>; <volume>118</volume>: <fpage>1229</fpage>–<lpage>1230</lpage>.</citation></ref>
<ref id="bibr38-0961203311429815"><label>38.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>MH</given-names></name></person-group>. <article-title>Pulmonary hypertension, systemic lupus erythematosus, and the contraceptive pill: another report</article-title>. <source>Ann Rheum Dis</source> <year>1987</year>; <volume>46</volume>: <fpage>159</fpage>–<lpage>161</lpage>.</citation></ref>
<ref id="bibr39-0961203311429815"><label>39.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jungers</surname><given-names>P</given-names></name><name><surname>Dougados</surname><given-names>M</given-names></name><name><surname>Pélissier</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1982</year>; <volume>25</volume>: <fpage>616</fpage>–<lpage>624</lpage>.</citation></ref>
<ref id="bibr40-0961203311429815"><label>40.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kawamura</surname><given-names>N</given-names></name><name><surname>Tsutsui</surname><given-names>H</given-names></name><name><surname>Fukuyama</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Severe pulmonary hypertension in a patient with systemic lupus erythematosus and minimal lupus activity</article-title>. <source>Intern Med</source> <year>2002</year>; <volume>41</volume>: <fpage>109</fpage>–<lpage>112</lpage>.</citation></ref>
<ref id="bibr41-0961203311429815"><label>41.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koyama</surname><given-names>S</given-names></name><name><surname>Ichiyoshi</surname><given-names>T</given-names></name><name><surname>Chino</surname><given-names>M</given-names></name><name><surname>Kanbayashi</surname><given-names>T</given-names></name></person-group>. <article-title>Systemic lupus erythematosus with pulmonary hypertension</article-title>. <source>Intern Med</source> <year>1996</year>; <volume>35</volume>: <fpage>39</fpage>–<lpage>42</lpage>.</citation></ref>
<ref id="bibr42-0961203311429815"><label>42.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marchesoni</surname><given-names>A</given-names></name><name><surname>Messina</surname><given-names>K</given-names></name><name><surname>Carrieri</surname><given-names>P</given-names></name><name><surname>Sinigaglia</surname><given-names>L</given-names></name><name><surname>Tosi</surname><given-names>S</given-names></name></person-group>. <article-title>Pulmonary hypertension and systemic lupus erythematosus</article-title>. <source>Clin Exp Rheumatol</source> <year>1983</year>; <volume>1</volume>: <fpage>247</fpage>–<lpage>250</lpage>.</citation></ref>
<ref id="bibr43-0961203311429815"><label>43.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>N</given-names></name><name><surname>Yamada</surname><given-names>A</given-names></name><name><surname>Harada</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>[A case of lupus erythematosus preceded by right heart failure due to pulmonary hypertension]</article-title>. <source>Kokyu To Junkan</source> <year>1991</year>; <volume>39</volume>: <fpage>1037</fpage>–<lpage>1041</lpage>.</citation></ref>
<ref id="bibr44-0961203311429815"><label>44.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ebrahim</surname><given-names>RA</given-names></name><name><surname>Jamsheer</surname><given-names>A</given-names></name><name><surname>Al-Banna</surname><given-names>R</given-names></name><name><surname>Al-Qari</surname><given-names>H</given-names></name></person-group>. <article-title>Pulmonary hypertension in SLE - A case report</article-title>. <source>Bahrain Medical Bulletin</source> <year>1999</year>; <volume>21</volume>: <fpage>27</fpage>–<lpage>29</lpage>.</citation></ref>
<ref id="bibr45-0961203311429815"><label>45.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Menon</surname><given-names>MA</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Ng</surname><given-names>SC</given-names></name></person-group>. <article-title>Primary pulmonary hypertension in systemic lupus erythematosus</article-title>. <source>Singapore Med J</source> <year>1985</year>; <volume>26</volume>: <fpage>544</fpage>–<lpage>549</lpage>.</citation></ref>
<ref id="bibr46-0961203311429815"><label>46.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Denton</surname><given-names>CP</given-names></name><name><surname>Humbert</surname><given-names>M</given-names></name><name><surname>Rubin</surname><given-names>L</given-names></name><name><surname>Black</surname><given-names>CM</given-names></name></person-group>. <article-title>Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions</article-title>. <source>Ann Rheum Dis</source> <year>2006</year>; <volume>65</volume>: <fpage>1336</fpage>–<lpage>1340</lpage>.</citation></ref>
<ref id="bibr47-0961203311429815"><label>47.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pines</surname><given-names>A</given-names></name><name><surname>Kaplinsky</surname><given-names>N</given-names></name><name><surname>Olchovsky</surname><given-names>D</given-names></name><name><surname>Rozenman</surname><given-names>J</given-names></name><name><surname>Frankl</surname><given-names>O</given-names></name></person-group>. <article-title>Pleuro-pulmonary manifestations of systemic lupus erythematosus: clinical features of its subgroups. Prognostic and therapeutic implications</article-title>. <source>Chest</source> <year>1985</year>; <volume>88</volume>: <fpage>129</fpage>–<lpage>135</lpage>.</citation></ref>
<ref id="bibr48-0961203311429815"><label>48.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>TN</given-names></name></person-group>. <article-title>Thrombi in antrum atrii dextri of human heart as clinically important source of chronic microembolisation to lungs</article-title>. <source>Br Heart J</source> <year>1983</year>; <volume>49</volume>: <fpage>122</fpage>–<lpage>132</lpage>.</citation></ref>
<ref id="bibr49-0961203311429815"><label>49.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>RQ</given-names></name><name><surname>Lei</surname><given-names>YX</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Liang</surname><given-names>F</given-names></name></person-group>. <article-title>[Clinical analysis of patients with systemic lupus erythematosus and concomitant pulmonary hypertension]</article-title>. <source>Nan Fang Yi Ke Da Xue Xue Bao</source> <year>2008</year>; <volume>28</volume>: <fpage>1860</fpage>–<lpage>1863</lpage>.</citation></ref>
<ref id="bibr50-0961203311429815"><label>50.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>SR</given-names></name><name><surname>Swinton</surname><given-names>JR</given-names></name><name><surname>Granton</surname><given-names>JT</given-names></name></person-group>. <article-title>Prognostic factors for survival in scleroderma associated pulmonary arterial hypertension</article-title>. <source>J Rheumatol</source> <year>2008</year>; <volume>35</volume>: <fpage>1584</fpage>–<lpage>1590</lpage>.</citation></ref>
<ref id="bibr51-0961203311429815"><label>51.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Swiston</surname><given-names>JR</given-names></name><name><surname>Johnson</surname><given-names>SR</given-names></name><name><surname>Granton</surname><given-names>JT</given-names></name></person-group>. <article-title>Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension: a systematic review of the literature</article-title>. <source>Respir Med</source> <year>2010</year>; <volume>104</volume>: <fpage>1588</fpage>–<lpage>1607</lpage>.</citation></ref>
<ref id="bibr52-0961203311429815"><label>52.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greenstone</surname><given-names>MA</given-names></name></person-group>. <article-title>Delayed diagnosis of systemic lupus erythematosus associated pulmonary hypertension</article-title>. <source>Br J Rheumatol</source> <year>1991</year>; <volume>30</volume>: <fpage>391</fpage>–<lpage>391</lpage>.</citation></ref>
<ref id="bibr53-0961203311429815"><label>53.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pietra</surname><given-names>GG</given-names></name><name><surname>Edwards</surname><given-names>WD</given-names></name><name><surname>Kay</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry</article-title>. <source>Circulation</source> <year>1989</year>; <volume>80</volume>: <fpage>1198</fpage>–<lpage>1206</lpage>.</citation></ref>
<ref id="bibr54-0961203311429815"><label>54.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fulmer</surname><given-names>JD</given-names></name><name><surname>Kaltreider</surname><given-names>HB</given-names></name></person-group>. <article-title>The pulmonary vasculitides</article-title>. <source>Chest</source> <year>1982</year>; <volume>82</volume>: <fpage>615</fpage>–<lpage>624</lpage>.</citation></ref>
<ref id="bibr55-0961203311429815"><label>55.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asherson</surname><given-names>RA</given-names></name><name><surname>Oakley</surname><given-names>CM</given-names></name></person-group>. <article-title>Pulmonary hypertension and systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>1986</year>; <volume>13</volume>: <fpage>1</fpage>–<lpage>5</lpage>.</citation></ref>
<ref id="bibr56-0961203311429815"><label>56.</label><citation citation-type="book"><person-group person-group-type="editor"><name><surname>Hughes</surname><given-names>GRV</given-names></name></person-group>. <source>The connective tissue diseases</source>, <edition>2nd ed</edition>. <publisher-loc>Oxford</publisher-loc>: <publisher-name>Blackwell Scientific</publisher-name>, <year>1983</year>.</citation></ref>
<ref id="bibr57-0961203311429815"><label>57.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Badui</surname><given-names>E</given-names></name><name><surname>Garcia-Rubi</surname><given-names>D</given-names></name><name><surname>Robles</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Cardiovascular manifestations in systemic lupus erythematosus. Prospective study of 100 patients</article-title>. <source>Angiology</source> <year>1985</year>; <volume>36</volume>: <fpage>431</fpage>–<lpage>441</lpage>.</citation></ref>
<ref id="bibr58-0961203311429815"><label>58.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>BM</given-names></name><name><surname>Zemp</surname><given-names>L</given-names></name><name><surname>Seifert</surname><given-names>B</given-names></name><name><surname>Hess</surname><given-names>OM</given-names></name></person-group>. <article-title>Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996</article-title>. <source>J Am Coll Cardiol</source> <year>1998</year>; <volume>31</volume>: <fpage>1650</fpage>–<lpage>1657</lpage>.</citation></ref>
<ref id="bibr59-0961203311429815"><label>59.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Funauchi</surname><given-names>M</given-names></name><name><surname>Shimadzu</surname><given-names>H</given-names></name><name><surname>Tamaki</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Survival study by organ disorders in 306 Japanese patients with systemic lupus erythematosus: results from a single center</article-title>. <source>Rheumatol Int</source> <year>2007</year>; <volume>27</volume>: <fpage>243</fpage>–<lpage>249</lpage>.</citation></ref>
<ref id="bibr60-0961203311429815"><label>60.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goupille</surname><given-names>P</given-names></name><name><surname>Fauchier</surname><given-names>L</given-names></name><name><surname>Babuty</surname><given-names>D</given-names></name><name><surname>Fauchier</surname><given-names>JP</given-names></name><name><surname>Valat</surname><given-names>JP</given-names></name></person-group>. <article-title>Precapillary pulmonary hypertension dramatically improved with high doses of corticosteroids during systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>1994</year>; <volume>21</volume>: <fpage>1976</fpage>–<lpage>1977</lpage>.</citation></ref>
<ref id="bibr61-0961203311429815"><label>61.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kawaguchi</surname><given-names>Y</given-names></name><name><surname>Hara</surname><given-names>M</given-names></name><name><surname>Harigai</surname><given-names>M</given-names></name><name><surname>Sakurada</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Kashiwazaki</surname><given-names>S</given-names></name></person-group>. <article-title>Corticosteroid pulse therapy in a patient with SLE and pulmonary hypertension</article-title>. <source>Clin Exp Rheumatol</source> <year>1998</year>; <volume>16</volume>: <fpage>510</fpage>–<lpage>510</lpage>.</citation></ref>
<ref id="bibr62-0961203311429815"><label>62.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karmochkine</surname><given-names>M</given-names></name><name><surname>Wechsler</surname><given-names>B</given-names></name><name><surname>Godeau</surname><given-names>P</given-names></name><name><surname>Brenot</surname><given-names>F</given-names></name><name><surname>Jagot</surname><given-names>JL</given-names></name><name><surname>Simonneau</surname><given-names>G</given-names></name></person-group>. <article-title>Improvement of severe pulmonary hypertension in a patient with SLE</article-title>. <source>Ann Rheum Dis</source> <year>1996</year>; <volume>55</volume>: <fpage>561</fpage>–<lpage>562</lpage>.</citation></ref>
<ref id="bibr63-0961203311429815"><label>63.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>A</given-names></name><name><surname>Samanta</surname><given-names>A</given-names></name><name><surname>Nichol</surname><given-names>FE</given-names></name></person-group>. <article-title>Primary pulmonary hypertension associated with systemic lupus erythematosus</article-title>. <source>Clin Rheumatol</source> <year>1991</year>; <volume>10</volume>: <fpage>320</fpage>–<lpage>322</lpage>.</citation></ref>
<ref id="bibr64-0961203311429815"><label>64.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>O</given-names></name><name><surname>Sitbon</surname><given-names>O</given-names></name><name><surname>Jaïs</surname><given-names>X</given-names></name><name><surname>Simonneau</surname><given-names>G</given-names></name><name><surname>Humbert</surname><given-names>M</given-names></name></person-group>. <article-title>Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension</article-title>. <source>Chest</source> <year>2006</year>; <volume>130</volume>: <fpage>182</fpage>–<lpage>189</lpage>.</citation></ref>
<ref id="bibr65-0961203311429815"><label>65.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jais</surname><given-names>X</given-names></name><name><surname>Launay</surname><given-names>D</given-names></name><name><surname>Yaici</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases</article-title>. <source>Arthritis Rheum</source> <year>2008</year>; <volume>58</volume>: <fpage>521</fpage>–<lpage>531</lpage>.</citation></ref>
<ref id="bibr66-0961203311429815"><label>66.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Minai</surname><given-names>O</given-names></name></person-group>. <article-title>An update in pulmonary hypertension in systemic lupus erythematosus - do we need to know about it?</article-title> <source>Lupus</source> <year>2009</year>; <volume>18</volume>: <fpage>92</fpage>–<lpage>92</lpage>.</citation></ref>
<ref id="bibr67-0961203311429815"><label>67.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pope</surname><given-names>J</given-names></name></person-group>. <article-title>An update in pulmonary hypertension in systemic lupus erythematosus - do we need to know about it?</article-title> <source>Lupus</source> <year>2008</year>; <volume>17</volume>: <fpage>274</fpage>–<lpage>277</lpage>.</citation></ref>
<ref id="bibr68-0961203311429815"><label>68.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoshio</surname><given-names>T</given-names></name><name><surname>Masuyama</surname><given-names>J</given-names></name><name><surname>Mimori</surname><given-names>A</given-names></name><name><surname>Takeda</surname><given-names>A</given-names></name><name><surname>Minota</surname><given-names>S</given-names></name><name><surname>Kano</surname><given-names>S</given-names></name></person-group>. <article-title>Endothelin-1 release from cultured endothelial cells induced by sera from patients with systemic lupus erythematosus</article-title>. <source>Ann Rheum Dis</source> <year>1995</year>; <volume>54</volume>: <fpage>361</fpage>–<lpage>365</lpage>.</citation></ref>
<ref id="bibr69-0961203311429815"><label>69.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haas</surname><given-names>C</given-names></name></person-group>. <article-title>[Pulmonary hypertension associated with systemic lupus erythematosus]</article-title>. <source>Bull Acad Natl Med</source> <year>2004</year>; <volume>188</volume>: <fpage>985</fpage>–<lpage>997</lpage>.</citation></ref>
<ref id="bibr70-0961203311429815"><label>70.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heresi</surname><given-names>GA</given-names></name><name><surname>Minai</surname><given-names>OA</given-names></name></person-group>. <article-title>Lupus-associated pulmonary hypertension: long-term response to vasoactive therapy</article-title>. <source>Respir Med</source> <year>2007</year>; <volume>101</volume>: <fpage>2099</fpage>–<lpage>2107</lpage>.</citation></ref>
<ref id="bibr71-0961203311429815"><label>71.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>P</given-names></name><name><surname>Grossman</surname><given-names>JM</given-names></name></person-group>. <article-title>Treatment of mixed connective tissue disease</article-title>. <source>Rheum Dis Clin North Am</source> <year>2005</year>; <volume>31</volume>: <fpage>549</fpage>–<lpage>565</lpage>.</citation></ref>
</ref-list>
</back>
</article>